<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21827">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02822729</url>
  </required_header>
  <id_info>
    <org_study_id>01171504</org_study_id>
    <nct_id>NCT02822729</nct_id>
  </id_info>
  <brief_title>A Long-term Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With OAG or OH: RENGE Study</brief_title>
  <official_title>A Long-term Open-label Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension : RENGE Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santen Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santen Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are to evaluate the long-term safety and intraocular
      pressure-lowering efficacy of DE-117 ophthalmic solution monotherapy and concomitant use of
      DE-117 ophthalmic solution with timolol ophthalmic solution 0.5% in patients with open angle
      glaucoma or ocular hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of adverse events</measure>
    <time_frame>Week 52</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Open Angle Glaucoma or Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>DE-117 ophthalmic solution (Group1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DE-117 ophthalmic solution (Group2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DE-117 ophthalmic solution + Timolol (Group3)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Concomitant Use</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DE-117 ophthalmic solution</intervention_name>
    <arm_group_label>DE-117 ophthalmic solution (Group1)</arm_group_label>
    <arm_group_label>DE-117 ophthalmic solution (Group2)</arm_group_label>
    <arm_group_label>DE-117 ophthalmic solution + Timolol (Group3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timolol ophthalmic solution</intervention_name>
    <arm_group_label>DE-117 ophthalmic solution + Timolol (Group3)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with open angle glaucoma or ocular hypertension

        Exclusion Criteria:

          -  Patients at risk of progression of visual field loss

          -  Patients with severe visual field defect

          -  Patients with any diseases that preclude participation in this study for safety
             reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Santen Pharmaceutical Co., Ltd</last_name>
    <phone>+81-6-4802-9336</phone>
    <email>clinical@santen.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santen Pharmaceutical Co., Ltd</last_name>
      <phone>+81-6-4802-9336</phone>
      <email>clinical@santen.co.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 3, 2016</lastchanged_date>
  <firstreceived_date>June 30, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
